Christopher Ton

US Patent:

20100068191, Mar 18, 2010

Filed:

Aug 14, 2009

Appl. No.:

12/541282

Inventors:

Alla Danilkovich - Columbia MD, US
Samson Tom - Baltimore MD, US
Christopher Ton - Baltimore MD, US
Zhanling Wang - West Chester PA, US
Randell G. Young - Ellicott City MD, US

International Classification:

A61K 45/00
A61P 43/00

US Classification:

424 937

Abstract:

One or more purified mesenchymal stem cell pharmaceutical compositions and methods of manufacture utilizing centrifugal filtration are disclosed. Threshold limits for intravenous administration of mesenchymal stem cell pharmaceutical compositions comprising residual animal products are also disclosed.

US Patent:

20120087933, Apr 12, 2012

Filed:

Oct 6, 2011

Appl. No.:

13/267363

Inventors:

Samson Tom - Basking Ridge NJ, US
Christopher Ton - Lansdale PA, US
Alla Danilkovitch - Columbia MD, US

International Classification:

A61K 35/28
A61P 37/06
A61P 29/00
A61P 5/14
C12N 5/0775
A61P 1/00
A61P 19/02

US Classification:

4241841, 435372

Abstract:

The present invention provides preparations of MSCs with important therapeutic potential. The MSC cells are non-primary cells with an antigen profile comprising less than about 1.25% CD45+ cells (or less than about 0.75% CD45+), at least about 95% CD105+ cells, and at least about 95% CD166+ cells. Optionally, MSCs of the present preparations are isogenic and can be expanded ex vivo and cryopreserved and thawed, yet maintain a stable and uniform phenotype. Methods are taught here of expanding these MSCs to produce a clinical scale therapeutic preparations and medical uses thereof.

US Patent:

20230089901, Mar 23, 2023

Filed:

Sep 23, 2022

Appl. No.:

17/934852

Inventors:

- Meyrin, CH
Robert E. NEWMAN - Sykesville MD, US
Samson TOM - Baltimore MD, US
Christopher TON - Lansdale PA, US
Zhanling WANG - West Chester PA, US
Randell G. YOUNG - Ellicott City MD, US

International Classification:

A61K 35/28
C12N 5/0775

Abstract:

One or more purified mesenchymal stem cell pharmaceutical compositions and methods of manufacture utilizing centrifugal filtration are disclosed. Threshold limits for intravenous administration of mesenchymal stem cell pharmaceutical compositions comprising residual animal products are also disclosed.

US Patent:

20200231936, Jul 23, 2020

Filed:

Dec 23, 2019

Appl. No.:

16/725677

Inventors:

- Meyrin, CH
Christopher Ton - Lansdale PA, US
Alla Danilkovitch - Columbia MD, US

Assignee:

Mesoblast International Sarl - Meyrin

International Classification:

C12N 5/0775
A61K 47/69
B82Y 5/00
A61K 49/18
A61K 49/04
A61K 41/00
A61K 35/28

Abstract:

The present invention provides preparations of MSCs with important therapeutic potential. The MSC cells are non-primary cells with an antigen profile comprising less than about 1.25% CD45+ cells (or less than about 0.75% CD45+), at least about 95% CD105+ cells, and at least about 95% CD166+ cells. Optionally, MSCs of the present preparations are isogenic and can be expanded ex vivo and cryo-preserved and thawed, yet maintain a stable and uniform phenotype. Methods are taught here of expanding these MSCs to produce a clinical scale therapeutic preparations and medical uses thereof.

US Patent:

20200197444, Jun 25, 2020

Filed:

Nov 25, 2019

Appl. No.:

16/694382

Inventors:

- Meyrin, CH
Robert E. Newman - Sykesvillen MD, US
Samson Tom - Baltimore MD, US
Christopher Ton - Lansdale PA, US
Zhanling Wang - West Chester PA, US
Randell Young - Ellicott City MD, US

International Classification:

A61K 35/28
C12N 5/0775

Abstract:

One or more purified mesenchymal stem cell pharmaceutical compositions and methods of manufacture utilizing centrifugal filtration are disclosed. Threshold limits for intravenous administration of mesenchymal stem cell pharmaceutical compositions comprising residual animal products are also disclosed.

US Patent:

20180291347, Oct 11, 2018

Filed:

Apr 4, 2018

Appl. No.:

15/945148

Inventors:

- Meyrin, CH
Christopher Ton - Lansdale PA, US
Alla Danilkovitch - Columbia MD, US

Assignee:

Mesoblast International Sarl - Meyrin

International Classification:

C12N 5/0775
B82Y 5/00

Abstract:

The present invention provides preparations of MSCs with important therapeutic potential. The MSC cells are non-primary cells with an antigen profile comprising less than about 1.25% CD45+ cells (or less than about 0.75% CD45+), at least about 95% CD105+ cells, and at least 95% CD166+ cells. Optionally, MSCs of the present preparations are isogenic and can be expanded ex vivo and cryo-preserved and thawed, yet maintain a stable and uniform phenotype. Methods are taught here of expanding these MSCs to produce a clinical scale therapeutic preparations and medical uses thereof.

US Patent:

20180008642, Jan 11, 2018

Filed:

May 23, 2017

Appl. No.:

15/602848

Inventors:

- Meyrin, CH
Samson Tom - Baltimore MD, US
Christopher Ton - Baltimore MD, US
Zhanling Wang - West Chester PA, US
Randell G. Young - Ellicott City MD, US

International Classification:

A61K 35/28
C12N 5/0775
A61K 35/12

Abstract:

One or more purified mesenchymal stem cell pharmaceutical compositions and methods of manufacture utilizing centrifugal filtration are disclosed. Threshold limits for intravenous administration of mesenchymal stem cell pharmaceutical compositions comprising residual animal products are also disclosed.

US Patent:

20150247122, Sep 3, 2015

Filed:

Mar 19, 2015

Appl. No.:

14/662344

Inventors:

- Meyrin, CH
Christopher Ton - Lansdale PA, US
Alla Danilkovitch - Columbia MD, US

International Classification:

C12N 5/0775

Abstract:

The present invention provides preparations of MSCs with important therapeutic potential. The MSC cells are non-primary cells with an antigen profile comprising less than about 1.25% CD45+ cells (or less than about 0.75% CD45+), at least about 95% CD105+ cells, and at least about 95% CD166+ cells. Optionally, MSCs of the present preparations are isogenic and can be expanded ex vivo and cryopreserved and thawed, yet maintain a stable and uniform phenotype. Methods are taught here of expanding these MSCs to produce a clinical scale therapeutic preparations and medical uses thereof.